#This Flexible Electronic Sticks To Your Skin And Can Measure Your Blood Flow The blood coursing through your arteries
when she saw the side effects of cancer and how the drugs used to kill cancer cells also killed other parts of the body.
Strangely shaped cells often indicate cancer. While this old, simple technique may seem a quaint throwback in the age of high-technology health care tools like genetic sequencing,
and potentially treating human diseases such as cancer, cardiovascular disease, neurodegenerative conditions and diabetes, which can be driven by mutations in control regions of the genome.
#Non-Genetic Cancer Mechanism Found Cancer can be caused solely by protein imbalances within cells, a study of ovarian cancer has found.
The discovery is a major breakthrough because genetic aberrations have been seen as the main cause of almost all cancer.
The research in Oncogene demonstrates that protein imbalance is a powerful prognostic tool, indicating whether or not patients are likely to respond to chemotherapy
led by scientists at the University of Leeds and The University of Texas MD Anderson Cancer Center, focused on the"Akt pathway,"a signaling pathway within cells that drives cancer formation and the spread of cancers
A conventional approach to diagnosing this cancer would be to look for genetic modification of the receptor
In this way, an imbalance in the amount of the two proteins can lead to cell proliferation and cancer formation.
whether you have a predisposition to cancer and, ultimately, use a precision medicine-based approach to develop a therapeutic approach.
which cancer can occur. We found that in cells where Grb2 is depleted, FGFR2 was vulnerable to Plc?
indicating that protein imbalance can have a role in metastasis, the spread of a cancer through the body.
1 was predictive of the progress of ovarian cancers in patients. Measuring the levels of the proteins in patient tissues followed by database analysis of clinical information from The Cancer Genome Atlas
and other sources revealed that a high level of Grb2 relative to Plc? 1 and FGFR2 was associated with a significantly more favorable prognosis than patients with elevated levels of Plc?
It involved researchers from the University of Leeds, The University of Texas MD Anderson Cancer Center and the UT Health Science Center at Houston t
which is the second most common cancer and accounts for over one-quarter of all cancer-related deaths.
"adds Russell Jones, Associate professor of Physiology at Mcgill University's Goodman Cancer Research Centre. The study suggests that nutrient availability in the organism,
and other nutrients, can impact cancer progression.""Our work shows that cancers can use alternative fuel sources to help drive their growth under stressful conditions,"notes Prof.
Jones."This remarkable flexibility is part of what makes cancer so deadly, but offers hope in finding new therapies.""
""Understanding the mechanisms used by cancer cells to adapt to their environment creates new possibilities to treat this deadly disease,
and the metabolic alterations in lung cancer cells will lead to innovations in treatment for non-small cell lung cancer, one of the most deadly types of cancer
Scientists at The Institute of Cancer Research, London, analyzed 177 tumor samples from patients with stage I non-seminomatous tumors enrolled in clinical trials through the Medical Research Council (MRC
Scientists at The Institute of Cancer Research (ICR found that three different features of the tumors were important indicators of relapse risk:
the levels of a molecule called CXCL12, the percentage of the tumor with an appearance of cancer stem cells and whether or not blood vessels were present in the tumor.
Professor of Cancer Molecular Pathology at The Institute of Cancer Research, London, said, "Our research has led to the development of a test that can detect patients that will benefit from treatment up front
Approaches such as this to minimize chemotherapy are particularly important for cancers like testicular cancer, which affect young adults who could live with the side-effects for decades."
"Professor Robert Huddart, Professor of Urological Cancer at The Institute of Cancer Research, London, and Consultant at The Royal Marsden NHS Foundation Trust, said,
We now need to test this prognostic index in larger groups of men in the clinic"The work was funded by the MRC with support from the National Cancer Research Institute Testis Cancer Clinical Studies Group,
and is published in Clinical Cancer Research h
#Artificial'skin'Provides Prosthetics With Sensation Using flexible organic circuits and specialized pressure sensors, researchers have created an artificial skin"that can sense the force of static objects.
#Protein Found In Malaria Could Help Stop Cancer Researchers have discovered how a protein from malaria could some day help stop cancer.
Researchers found that the same type of sugar molecule also is present in many types of cancer.
It's somehow fitting that a disease as destructive as malaria might be exploited to treat another dreaded disease like cancer."
and lung cancers,"said Dr. Nhan Tran, an Associate professor in Translational Genomics Research Institute (TGEN)' s Cancer and Cell biology Division,
it would bind with the oncofetal protein in the cancer, delivering the drug to the tumor."
"Scientists have spent decades trying to find biochemical similarities between placenta tissue and cancer, but we just didn't have the technology to find it,
""This is an extraordinary finding that paves the way for targeting sugar molecules in pediatric and adulthood human cancer,
"said Poul Sorensen, a UBC professor of Pathology and Laboratory Medicine and distinguished scientist with the BC Cancer Agency and co-senior investigator on the study y
which have shown promise in treating everything from seizures and inflammation to cancer and parkinson disease.
and even certain cancers. The winners of the fifth annual Google Science Fair were announced live from Google Headquarters in Mountain view
"It's a totally new approach to cancer, and we're working to test it in human patients
it can actually turn leukaemia cells into cancer killers. The antibody in question binds to a receptor called TPO-or thrombopoietin-which is found on most acute myeloid leukaemia cells.
which suggests that it could work as a targeted cancer therapy. And for some reason, the NK cells also didn't seem to attack all cancer types-only their former brethren.
That's both good and bad, as it means they're more specific and are less likely to have side effects.
The team is also screening for antibodies that could have a similar effect on other cancer types.
#Scientists finally figure out the structure of a key cancer-driving enzyme It been a long time coming,
an enzyme complex known to play a crucial role in the development of several types of cancer.
and therefore triggering the development of cancer and disease has been practically impossible. But now, for the first time, Liu and his colleagues have reproduced the 3d atomic structure of PRC2 crystals,
#New electronic sensor can detect ovarian cancer in your breath Your breath says more about you than you might think-not just how inebriated you are or
A new type of sensor that can'sniff out'traces of ovarian cancer in a patient's breath has been developed by researchers in Israel,
We've seen the idea of a breathalyser being used to detect different types of cancer before,
Based on some initial testing, Kahn and her colleagues were able to correctly detect ovarian cancer in 82 percent of cases,
only high-risk patients are tested for ovarian cancer to reduce the chance of false positives, and seeing as most women don get symptoms until the disease is advanced quite,
With further research, Kahn thinks the same technique could be used to test for different types of cancer,
Ovarian cancer currently accounts for around 3 percent of cancers among women and with around 200,000 cases reported in the US each year,
However, it causes more deaths than any other cancer of the female reproductive system, and so new techniques to battle it would have a significant impact n
the researchers tested for the first time to pre-treat undifferentiated mouse embryonic stem cells with mitomycin C a drug already prescribed to treat cancer.
#One dollar blood test using gold nanoparticles outperforms PSA screen for prostate cancer, study suggests The simple test developed by University of Central Florida scientist Qun"Treen"Huo holds the promise of earlier detection of one of the deadliest cancers among men.
It would also reduce the number of unnecessary and invasive biopsies stemming from the less precise PSA test that's now used."
"said Dr. Inoel Rivera, a urologic oncologist at Florida Hospital Cancer Institute, which collaborated with Huo on the recent pilot studies."
certain cancer biomarkers cling to the surface of the tiny particles, increasing their size and causing them to clump together.
whether a patient has prostate cancer and how advanced it may be. And although it uses gold,
If we can catch this cancer in its early stages, the impact is going to be big."
"After lung cancer, prostate cancer is the second-leading killer cancer among men, with more than 240,000 new diagnoses and 28,000 deaths every year.
"Potentially, we could have a universal screening test for cancer, "she said.""Our vision is to develop an array of blood tests for early detection and diagnosis of all major cancer types,
and these blood tests are all based on the same technique and same procedure.""Huo co-founded Nano Discovery Inc.,a startup company headquartered in a UCF Business Incubator,
"But many diseases, like cancer, cardiovascular disease or neurodegenerative conditions, have a much more complex genetic component.
which would include rapid detection of cancer or monitoring toxins in the water supply,"says Brennan."
and MIT's Koch Institute for Integrative Cancer Research, found that a subset of glioblastoma tumor cells is dependent on a particular enzyme that breaks down the amino acid glycine.
#Study on new treatment for prostate cancer Published in The british Journal of Cancer (BJC), the study is the first time low temperature plasmas (LTPS) have been applied on cells grown directly from patient tissue samples.
It is the result of a unique collaboration between the York Plasma Institute in the Department of physics and the Cancer Research Unit (CRU) in York Department of biology.
and prostate cancer tissue cells from a single patient, the study allowed for direct comparison of the effectiveness of the treatment.
Scientists discovered that LTPS may be a potential option for treatment of patients with organ confined prostate cancer
espite continual improvement and refinement, long term treatment for prostate cancer is recognised still as inadequate. In the case of early stage organ confined tumours, patients may be treated with a focal therapy, for example cryotherapy, photodynamic therapy,
This may be due to the inherent radio-resistance of a small fraction of the tumour the cancer stem-like cells.
we have presented the first experimental evidence promoting the potential of LTP as a future focal cancer therapy treatment for patients with early stage prostate cancer.
LTP could be used to treat cancer patients within 10-15 years 1
#Researchers deliver large particles into cells at high speed The researchers created a highly efficient automated tool that delivers nanoparticles, enzymes, antibodies, bacteria and other"large-sized"cargo into mammalian cells at the rate
#Breakthrough finds molecules that block previously'undruggable'protein tied to cancer The findings, which could lead to a new class of cancer drugs,
The results hold promise for treating a broad array of cancers in people. The researcher said Hur has been detected at high levels in almost every type of cancer tested,
including cancers of the colon, prostate, breast, brain, ovaries, pancreas and lung.""Hur inhibitors may be useful for many types of cancer,
"Xu said.""Since Hur is involved in many stem cell pathways, we expect Hur inhibitors will be active in inhibiting'cancer stem cells,
'or the seeds of cancer, which have been a current focus in the cancer drug discovery field."
"Hur has been studied for many years, but until now no direct Hur inhibitors have been discovered, according to Xu.""The initial compounds reported in this paper can be optimized further
and developed as a whole new class of cancer therapy, especially for cancer stem cells, "he said."
"The success of our study provides a first proof-of-principle that Hur is druggable,
"A cancer-causing gene, or oncogene, makes RNA, which then makes an oncoprotein that causes cancer
or makes cancer cells hard to kill, or both,"Xu said.""This is the problem we're trying to overcome with precision medicine."
not a well-defined pocket seen in other druggable proteins targeted by many current cancer therapies."
and involved the collaboration of chemists, cancer biologists, computer modeling experts, biochemists and biophysicists at KU--notably the labs of Xu, Jeffrey Aub in the Department of Medicinal Chemistry and Jon Tunge in the Department of chemistry.
For Xu, the findings are reflective of a personal commitment to improving odds for people diagnosed with cancer
"Trained as medical doctor and Ph d.,with both a grandfather and an uncle who died of cancer,
I devoted my career to cancer research and drug discovery--aiming to translate discovery in the lab into clinical therapy,
to help cancer patients and their families, "he said.""We hope to find a better therapy--and eventually a cure--for cancer
#Study revises theory of how PTEN, a critical tumor suppressor, shuts off growth signals Today,
and could help scientists design more effective drugs to counteract cancer's hallmark trait, uncontrolled cellular growth."
"A whole generation of cancer investigators, including me, has been taught that PTEN performs its crucial role at the plasma membrane,
"said Dr. Lisa Baumbach-Reardon, an Associate professor of TGEN's Integrated Cancer Genomics Division and the study's senior author.
#Breakthrough in cancer research: Cancer-suppressing proteins The research was conducted in the laboratory of Distinguished Professor Aaron Ciechanover, of the Technion Rappaport Faculty of medicine.
The team was led by research associate Dr. Yelena Kravtsova-Ivantsiv and included additional research students and colleagues,
-B has been identified as a link between inflammation and cancer. The hypothesis of the connection between inflammatory processes and cancer was suggested first in 1863 by German pathologist Rudolph Virchow,
and has been confirmed over the years in a long series of studies. Ever since the discovery (nearly 30 years ago) of NF?
Professor Ciechanover, who is also the president of the Israel Cancer Society, notes that many more years are required"to establish the research
#Researchers find protein that may signal more aggressive prostate cancers Biomarkers in the body are analogous to the warning lights in cars that signal something might need repairing.
"In the context of prostate cancer) there's a big interest in trying to find biomarkers to discriminate between aggressive and nonaggressive disease,
Prostate cancer can grow so slowly the carrier dies of natural causes before the cancer spreads,
and could provide a potential new drug target for prostate cancer, "Franceschi said.""It could also be a potential biomarker to discriminate between fast and slow growing tumors."
whose research lab mainly studies bone formation, not cancer.""We discovered this regulatory mechanism in bone cells,
"This is the first paper the lab has published on cancer.""The idea is that adding a phosphate group, a process called phosphorylation, to the protein Runx2,
whose function is to produce bone has this unusual function in prostate cancer, "Franceschi said.
Franceschi's lab also collaborated with researchers in Italy to analyze tissue samples from 129 patients with prostate cancer.
which suggests that Runx2 phosphorylation is associated closely with the more aggressive forms of prostate cancer.
The next step is to establish an actual cause-effect relationship between Runx2 phosphorylation and prostate cancer.
To do this they will compare prostate cancer formation in normal mice and mice lacking Runx2 in their prostates.
Worldwide, prostate cancer is the second-most common cancer in men, according to the World Cancer Research Fund International.
In the U s.,about 221,000 new cases of prostate cancer will be diagnosed in 2015 resulting in roughly 27,500 deaths s
"The global burden of cancer, limited access to prompt pathology services in many regions and emerging cell profiling technologies increase the need for low-cost,
"says Cesar Castro, MD, of the MGH Cancer Center and Center for Systems Biology, co-lead author of the report."
"The emerging genomic and biological data for various cancers, which can be essential to choosing the most appropriate therapy,
a sample of blood or tissue is labeled with microbeads that bind to known cancer-related molecules
along with those used for clinical diagnosis--using microbeads tagged with antibodies against three published markers of cervical cancer.
and depth of cancer screening in a way that is feasible and sustainable for resource limited-settings, "says Ralph Weissleder, MD, Phd, director of the MGH Center for Systems Biology (CSB) and co-senior author of the paper."
the discovery opens new lines of inquiry about the Ash1l gene's potential role in cancers known to involve other members of the same gene family,
"Leukemia is a cancer of the body's blood-forming tissues, so it's an obvious place that we plan to look at next.
and radiation used to treat cancer. The replacement of these cells through bone marrow transplantation is the only widely established therapy involving stem cells in human patients.
including those whose blood stem cells are killed off by cancer treatments. But work continues in the laboratory setting."
#New biomarker for uterine cancer discovered Researchers at Uppsala University have, together with researchers from Turku and Bergen, discovered a new biomarker
which makes it possible to identify women with uterine cancer who have a high risk of recurrence.
Endometrial cancer of the uterus is the most common form of gynecologic cancer in Europe and North america.
The current study looks at the amount of protein ASRGL1 present in the tumour cells in uterine cancer.
Turku and Bergen and is collected based on samples from 500 women who were diagnosed with uterine cancer between the years 1981 and 2007.
or partially lost ASRGL1 in the tumour cells had a much higher risk of the cancer recurring
'I view the results as a first step towards personal treatment of uterine cancer. Today, 10-15 per cent of the patients suffer recurrences,
It was within The Human Protein Atlas project that the expression of the ASRGL1 protein was mapped first in the human body's normal tissues and in different forms of cancer.
and cancer Scientists have discovered a protein that plays a central role in promoting immunity to viruses
and cancer, opening the door to new therapies. Experiments in mice and human cells have shown that the protein promotes the proliferation of cytotoxic T cells,
but when faced with serious infections or advanced cancer, they are often unable to proliferate in large enough quantities to fight the disease.
and were more resistant to cancer. They also produced more of a second type of T cells,
Genetically engineering T cells to augment their ability to fight cancer has been a goal for some time and techniques for modifying them already Exist by introducing an active version of the LEM gene into the T cells of cancer patients,
we hope we can provide a robust treatment for patients. ext we will test the therapy in mice,
and unlocked an unexpected way of enhancing the ability of our immune system to fight viruses or cancers.
This discovery has immediate consequences for the delivery of innovative therapeutic approaches to cancer. Its ramifications,
he discovery of a protein that could boost the immune response to not only cancer, but also to viruses, is a fascinating one.
and nivolumab against ipilimumab alone in previously untreated patients, were presented today at the 2015 Annual Meeting of the American Association for Cancer Research
who is also director of the Melanoma Center at the Dana-Farber Cancer Institute.""It's very encouraging to see that pattern reflected in this trial with previously untreated patients."
"Rationally combined immunotherapies hold great promise for cancer treatment as long as their side effects can be managed.""Ipilimumab interferes with a process by
which primarily affects boys, causes bleeding, severe and recurrent infections, severe eczema and in some patients autoimmune reactions and the development of cancer.
Research from Rutgers Cancer Institute of New jersey shows genomic profiling identifies genomic mutations in a gene associated with a rare subset of breast cancer--mutations that cannot otherwise be identified with standard clinical analysis of cells and tissue.
being presented as part of a poster presentation at the Annual Meeting of the American Association for Cancer Research (AACR) being held in Philadelphia,
Invasive lobular carcinoma is a cancer that starts in the lobules, an area of the breast where milk is produced.
As part of the precision medicine initiative at the Cancer Institute of New jersey, investigators--which include colleagues from Rutgers Robert Wood Johnson Medical school and RUCDR Infinite Biologics, the world's largest university-based biorepository,
With genomic sequencing detecting ERBB2 alterations in this form of cancer, we have an opportunity to identify anticancer therapies that would specifically target that abnormality
standard of care laboratory testing for breast cancer,"says lead author Kim M. Hirshfield, MD, Phd, breast medical oncologist at the Cancer Institute and assistant professor of medicine at Rutgers
Utilizing the invasive breast cancer data set of 962 cases in The Cancer Genome Atlas all breast cancers with alterations in the CDH1 gene (that gives instructions to make a protein that causes cancer cells to stick to one another
An additional 16 cases from the Cancer Institute were evaluated using an advanced form of tumor DNA sequencing at RUCDR.
Of 116 eligible breast cancers from The Cancer Genome Atlas 86 were invasive lobular breast cancer. Of that number, 21 cases were found to be the pleomorphic type.
There were no significant differences in the frequency of the other gene alterations examined between the two types of cancer.
Data from the additional 16 cases from the Cancer Institute validate the findings observed on breast cancers from The Cancer Genome Atlas."
"In identifying a specific abnormality in a patient's cancer instead of the overall organ where it first presented,
the opportunity exists to provide tailored therapies for patients,"notes Lorna Rodriguez, MD, Phd, director of the precision medicine initiative at the Cancer Institute and professor of obstetrics, gynecology and reproductive sciences
It is our aim at Rutgers Cancer Institute of New jersey to build upon this work,"notes senior author of the work, Shridar Ganesan, MD, Phd, associate director for translational science at the Cancer Institute
"Prof Shirley Hodgson, Professor of Cancer Genetics, St george's University of London, said:""I think that this is a significant departure from currently accepted research practice.
could allow biomedical engineers to identify appropriate binding sites for drugs used to treat cancer and other diseases.
The device is intended for use in remote laboratory settings to diagnose various types of cancers and nervous system disorders
#Uncovering new functions of a gene implicated in cancer growth opens new therapeutic possibilities Two decades ago,
was also present in cancer patients and contributing to tumor progression. The present study reveals another way that Id1 works, hijacking a normal pathway in immune cell development and interfering with the entire immune system, starting in the bone marrow.
and instead, cancer is allowed to grow, spread and thrive.""Targeting Id1 offers the potential to restore overall immune function,
Given the increased incidence and death rates tied to advanced stage metastatic cancers, there is also an increased urgency to understand how pro-metastatic, immunosuppressive mechanisms,
and allowing cancer to grow and spread unabated.""Normally, the bone marrow produces, among other immune cell types, dendritic cells,
who was a Fulbright Cancer Research Fellow at Cornell University in Dr. Lyden's lab."But when TGF?
allow cancer to more readily grow and spread. The researchers validated this finding in advanced melanoma patients,
who also has appointments in the Sandra and Edward Meyer Cancer Center and the Gale and Ira Drukier Institute for Children's Health at Weill Cornell Medical College."
"This will improve vaccine development, lead to better treatment outcomes and ultimately benefit cancer patients
"SIRT1 is known to be expressed abnormally in a variety of cancers and might be a good target for therapy.
Ubiquitin-proteasome inhibitors have already been used successfully in cancer therapy and clinical trials. Therefore, this research might provide molecular bases
and insights for developing additional therapeutic strategies in the future,"explained Ed Seto, Ph d.,senior member of the Cancer Biology and Evolution Program at Moffitt t
The new work also reveals more about certain cancers that arise when these processes go astray, for example,
"Both the Wnt and Activin signaling processes operate differently in cancer, compared to stem cells.
The aberrant behavior of the Activin process, meanwhile, is tied to the metastasis of many cancers."
NONO helps to mend the damage The study appeared as advanced online publication on Oncogene, a journal in cancer research from the Nature Publishing Group.
or transmitted to daughter cells during mitosis. Luigi Alfano, Phd of the National Cancer Institute of Naples-Pascale Foundation-CROM-Cancer Research center of Mercogliano,
"Considering that many studies are identifying NONO alterations in cancer, our findings will likely help to shed light on the molecular mechanisms of tumorigenesis, especially in tumour types like melanoma, in which exposure to UV radiations plays such a prominent part.
such as common chemotherapy agents,"states Francesca Pentimalli Phd from the National Cancer Institute of Naples co-corresponding of the study with Antonio Giordano,
Director of the Sbarro Institute for Cancer Research and Molecular Medicine, at Temple University, Philadelphia a
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011